Workflow
SYNERGY(300636)
icon
Search documents
同和药业(300636) - 招商证券股份有限公司关于江西同和药业股份有限公司增资参股公司暨关联交易的核查意见
2025-04-24 10:53
招商证券股份有限公司 关于江西同和药业股份有限公司 增资参股公司暨关联交易的核查意见 招商证券股份有限公司(以下简称"招商证券")作为江西同和药业股份有限 公司(以下简称"同和药业"、"公司")向特定对象发行股票的保荐机构,根据《证 券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳 证券交易所上市公司自律监管指引第 13 号—保荐业务》等有关规定,对公司增 资参股公司事项进行了核查,具体情况如下: 一、 本次关联交易概述 1、杭州渤雅生物医药有限公司(以下简称"杭州渤雅")系公司持股 16.3366% 的参股公司,拟进行新一轮融资,计划融资 2000 万,拟引入江西同和药业股份 有限公司(以下简称"公司"或"同和")及其他投资者,投前估值为 7000 万 元。本公司拟以自有资金 1100 万元增资,其中 105.8095 万元计入注册资本, 994.1905 万元计入资本公积。增资完成后杭州渤雅注册资本变更为 865.7139 万 元,同和占比为 24.9285%。 2、鉴于公司董事长兼总经理庞正伟先生之关联人为 ...
同和药业(300636) - 招商证券股份有限公司关于江西同和药业股份有限公司调整公司募集资金投资项目实施进度核查意见
2025-04-24 10:53
招商证券股份有限公司 关于江西同和药业股份有限公司 调整公司募集资金投资项目实施进度的核查意见 招商证券股份有限公司(以下简称"招商证券")作为江西同和药业股份有限 公司(以下简称"同和药业"、"公司")向特定对象发行股票的保荐机构,根据《证 券发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金 管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交 易所上市公司自律监管指引第 13 号—保荐业务》等有关规定,对公司调整募集 资金投资项目实施进度事项进行了核查,具体情况如下: 一、 募集资金基本情况 根据公司 2022 年 7 月 1 日召开的第三届董事会第十次会议审议通过的《关 于公司符合向特定对象发行 A 股股票条件的议案》《关于公司 2022 年度向特定 对象发行 A 股股票方案的议案》及与本次发行相关的其他议案、2022 年 7 月 18 日召开的 2022 年第二次临时股东大会审议通过的《关于公司符合向特定对象发 行 A 股股票条件的议案》《关于公司 2022 年度向特定对象发行 A 股 ...
同和药业(300636) - 独立董事2024年度述职报告(彭昕)
2025-04-24 10:51
江西同和药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表: 本人作为江西同和药业股份有限公司(以下简称"公司")的独 立董事,在任职期间严格按照《公司法》、《证券法》、《上市公司 治理准则》、《上市公司独立董事管理办法》和《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规,以及《公司章程》、《独立董事制度》等规定,在 2024 年度 工作中,诚实、勤勉、独立的履行职责,积极出席相关会议,认真审 议董事会各项议案,对公司重大事项发表了独立意见,充分发挥了独 立董事及各专业委员会委员的作用,切实维护了公司和股东特别是中 小股东的利益,较好的发挥了独立董事的独立性和专业性作用。根据 中国证监会发布的《上市公司独立董事管理办法》和深圳证券交易所 发布的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》有关要求,现将 2024 年度本人任职期间履行独立 董事职责情况报告如下: 一、 出席会议情况: 2024年度,本着勤勉尽责的态度,本人积极参加公司召开的股东 大会、董事会,认真审阅会议材料,积极参与各议题的讨论并提出合 理建议,以谨 ...
同和药业(300636) - 独立董事2024年度述职报告(李国平)
2025-04-24 10:51
江西同和药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表: 本人作为江西同和药业股份有限公司(以下简称"公司")的独 立董事,在任职期间严格按照《公司法》、《证券法》、《上市公司 治理准则》、《上市公司独立董事管理办法》和《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规,以及《公司章程》、《独立董事制度》等规定,在 2024 年度 工作中,诚实、勤勉、独立的履行职责,积极出席相关会议,认真审 议董事会各项议案,对公司重大事项发表了独立意见,充分发挥了独 立董事及各专业委员会委员的作用,切实维护了公司和股东特别是中 小股东的利益,较好的发挥了独立董事的独立性和专业性作用。根据 中国证监会发布的《上市公司独立董事管理办法》和深圳证券交易所 发布的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》有关要求,现将 2024 年度本人任职期间履行独立 董事职责情况报告如下: 一、 出席会议情况: 2024年度,本着勤勉尽责的态度,本人积极参加公司召开的股东 大会、董事会,认真审阅会议材料,积极参与各议题的讨论并提出合 理建议,以谨 ...
同和药业(300636) - 独立董事2024年度述职报告(宛虹)
2025-04-24 10:51
江西同和药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表: 本人作为江西同和药业股份有限公司(以下简称"公司")的独 立董事,在任职期间严格按照《公司法》、《证券法》、《上市公司 治理准则》、《上市公司独立董事管理办法》和《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规,以及《公司章程》、《独立董事制度》等规定,在 2024 年度 工作中,诚实、勤勉、独立的履行职责,积极出席相关会议,认真审 议董事会各项议案,对公司重大事项发表了独立意见,充分发挥了独 立董事及各专业委员会委员的作用,切实维护了公司和股东特别是中 小股东的利益,较好的发挥了独立董事的独立性和专业性作用。根据 中国证监会发布的《上市公司独立董事管理办法》和深圳证券交易所 发布的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》有关要求,现将 2024 年度本人任职期间履行独立 董事职责情况报告如下: 一、 出席会议情况: 2024年度,本着勤勉尽责的态度,本人积极参加公司召开的股东 大会、董事会,认真审阅会议材料,积极参与各议题的讨论并提出合 理建议,以谨 ...
同和药业:2024年报净利润1.07亿 同比增长0.94%
Tong Hua Shun Cai Bao· 2025-04-24 10:39
一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益(元) | 0.2538 | 0.2786 | -8.9 | 0.3084 | | 每股净资产(元) | 5.48 | 5.26 | 4.18 | 3.77 | | 每股公积金(元) | 2.97 | 3 | -1 | 1.55 | | 每股未分配利润(元) | 1.36 | 1.17 | 16.24 | 1.19 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 7.59 | 7.22 | 5.12 | 7.2 | | 净利润(亿元) | 1.07 | 1.06 | 0.94 | 1.01 | | 净资产收益率(%) | 4.70 | 6.06 | -22.44 | 9.18 | 数据四舍五入,查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有: 9740.41万股,累计占流通股比: 26.73%,较上期变化: -1314.4 ...
同和药业:拟以1100万元增资杭州渤雅,持股比例提升至24.9285%
news flash· 2025-04-24 10:30
同和药业(300636)公告,公司拟以自有资金1100万元增资杭州渤雅生物医药有限公司,其中105.81万 元计入注册资本,994.19万元计入资本公积。增资完成后,杭州渤雅注册资本变更为865.71万元,同和 药业占比提升至24.9285%。本次交易构成关联交易,尚需提交股东大会审议。杭州渤雅成立于2023年 11月29日,注册资本673.33万元,主要财务数据显示,截至2025年3月31日,资产总额754.67万元,净资 产741.95万元;2025年1-3月净利润-84.85万元。 ...
同和药业:2025年第一季度净利润2078.14万元,同比下降52.30%
news flash· 2025-04-24 10:30
同和药业(300636)公告,2025年第一季度营收为1.87亿元,同比下降9.47%;净利润为2078.14万元, 同比下降52.30%。同日公告,2024年营业收入为7.59亿元,同比增长5.09%。归属于上市公司股东的净 利润为1.07亿元,同比增长0.57%。公司拟向全体股东每10股派发现金红利0.4元(含税),送红股0股(含 税),以资本公积金向全体股东每10股转增0股。 ...
同和药业(300636) - 2024 Q4 - 年度财报
2025-04-24 10:30
Financial Performance - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2024, representing a year-on-year growth of 15%[15]. - The company's operating revenue for 2024 reached ¥758,890,499.03, representing a 5.09% increase compared to ¥722,138,705.43 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥106,584,102.17, a slight increase of 0.57% from ¥105,983,257.15 in 2023[20]. - The company achieved a sales revenue of 758.89 million yuan in the reporting period, representing a year-on-year growth of 5.09%[64]. - The external sales revenue reached 614.02 million yuan, an increase of 6.76% compared to the same period last year[64]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in Q1 2024, totaling 1.5 billion RMB[130]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between $900 million and $950 million[126]. - The company reported a gross margin of 45%, indicating strong operational efficiency[130]. Research and Development - The company is investing 50 million yuan in R&D for new pharmaceutical products in 2024[15]. - The average R&D investment over the past three years accounts for 8.34% of sales, indicating a strong commitment to innovation and technology development[34]. - The R&D team consists of over 500 professionals, ensuring a robust pipeline of new products and technologies[55]. - Research and development investment amounted to 59.45 million yuan, accounting for 7.83% of the current operating revenue, maintaining a high investment level[64]. - The company is currently in the verification phase for multiple R&D projects aimed at enhancing product competitiveness and market presence[80]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development in 2024[130]. - The company has completed 18 technology development and process optimization projects during the reporting period, with 12 APIs and 8 intermediates undergoing pilot and trial production[68]. Market Expansion - The company aims to expand its market presence in Southeast Asia, targeting a 20% increase in sales in that region by 2025[15]. - The company is actively expanding into domestic markets, having submitted multiple projects for approval with several large and medium-sized pharmaceutical companies[34]. - The company plans to maintain a balance between entering high-end markets for higher sales prices and retaining competitiveness in low-end markets[106]. - The company will prioritize international markets for product sales while also investing more resources to expand its domestic market presence[107]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the fiscal year[126]. - Market expansion plans include entering two new regions, aiming for a 10% market share in each by the end of 2024[130]. Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring a coordinated and balanced mechanism among these entities[136]. - The company has appointed three independent directors to enhance the objectivity and fairness of board decisions[136]. - The company has a complete set of governance regulations, including articles of association and rules for shareholders' meetings, board meetings, and supervisory meetings[136]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[134]. - The company is committed to improving its internal control systems to enhance governance levels[136]. - The company has established a complete and independent financial institution, with a sufficient number of dedicated financial accounting personnel and an independent accounting system and financial management system[146]. Environmental and Safety Management - The company emphasizes environmental protection and has advanced wastewater and air treatment capabilities, with a wastewater treatment capacity of 1,500 tons per day in one plant[61]. - The company has established a comprehensive safety management system, including a safety production committee led by the general manager, to ensure compliance with safety regulations[120]. - The company is continuously investing in environmental protection facilities and optimizing production processes to meet increasingly stringent environmental standards[120]. Employee Management and Compensation - The company emphasizes enhancing employee performance through a competitive compensation policy, including salaries, benefits, and performance-based bonuses[177]. - The training program aims to improve employee skills and competencies, focusing on regular training, professional skills, and management knowledge[178]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management during the reporting period amounted to 6.8491 million yuan[164]. - The highest remuneration was received by the Chairman and General Manager, Mr. Pang Zhengwei, totaling 928,100 yuan[164]. - The company has a total of 1,418 employees, with a professional composition including 717 production personnel, 30 sales personnel, 541 technical personnel, 9 financial personnel, and 121 administrative personnel[175]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[15]. - The company plans to invest $100 million in marketing to support new product launches and market expansion efforts[126]. - The company aims to conduct timely mergers and acquisitions to extend its industry chain and enhance its scale and strength[116]. - The company has completed CDE approvals for several products, including Venlafaxine Hydrochloride and Celecoxib, positioning itself as a major supplier in the domestic market[41]. Risks and Challenges - The company has identified key risks including regulatory changes and market competition, which may impact future performance[5]. - The company faces risks related to the loss of core technical personnel, which could impact its competitive advantage and operational stability[123]. - The company's export revenue constitutes a significant portion of its total revenue, making it vulnerable to exchange rate fluctuations, particularly with the appreciation of the RMB against the USD[124].
同和药业(300636) - 2025 Q1 - 季度财报
2025-04-24 10:30
Financial Performance - The company's revenue for Q1 2025 was ¥186,897,547.53, representing a decrease of 9.47% compared to ¥206,454,983.02 in the same period last year[5] - Net profit attributable to shareholders was ¥20,781,376.97, down 52.30% from ¥43,562,751.14 year-on-year[5] - Basic and diluted earnings per share decreased by 52.27% to ¥0.0495 from ¥0.1037 in the same period last year[5] - The operating profit for the current period is CNY 22,045,134.74, down from CNY 49,031,953.90, reflecting a decline of 55.1%[23] - The total comprehensive income attributable to the parent company is CNY 20,781,376.97, down from CNY 43,562,751.14 in the previous period[23] Cash Flow - The net cash flow from operating activities increased by 19.91% to ¥35,664,255.22, compared to ¥29,743,589.13 in the previous year[11] - Cash flow from operating activities generated a net amount of CNY 35,664,255.22, an increase of 19.7% from CNY 29,743,589.13 in the previous period[25] - The net cash flow from investing activities increased by 110.82% to ¥16,089,848.66, compared to a negative cash flow of ¥148,676,249.14 in the previous year[11] - Cash flow from investing activities yielded a net inflow of CNY 16,089,848.66, compared to a net outflow of CNY 148,676,249.14 in the previous period[25] - Cash flow from financing activities resulted in a net inflow of CNY 78,708,229.72, up from CNY 150,196,833.20 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,421,287,186.43, an increase of 3.06% from ¥3,319,551,672.71 at the end of the previous year[5] - Total liabilities increased to ¥1,091,757,923.63 from ¥1,010,803,786.88, reflecting an increase of 8.0%[20] - The company's cash and cash equivalents increased to ¥306,214,227.30 from ¥176,384,468.01, representing a growth of 73.5%[19] - Total cash and cash equivalents at the end of the period amounted to CNY 296,214,227.30, down from CNY 525,619,976.92 in the previous period[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,278[13] - The largest shareholder, Pang Zhengwei, holds 14.71% of shares, totaling 62,027,337 shares, with 46,520,503 shares under pledge[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 13.17% of shares, totaling 55,511,352 shares[13] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.58% of total shares[13] Research and Development - Research and development expenses rose by 37.39% to ¥14,140,941.15, primarily due to increased labor costs and material consumption[10] - Research and development expenses rose significantly to ¥14,140,941.15, compared to ¥10,292,403.05 in the previous period, reflecting a 37.4% increase[22] - The company is currently undergoing internal renovations for the quality inspection and research and development building[17] Operational Insights - Total operating revenue for the current period is ¥186,897,547.53, a decrease of 9.4% from ¥206,454,983.02 in the previous period[22] - Total operating costs increased to ¥161,677,017.83, up 7.0% from ¥150,662,133.88 in the previous period[22] - The company's net profit margin is under pressure due to rising costs, with operating costs outpacing revenue growth[22] - The company has maintained a stable equity position, with total equity increasing to ¥2,329,529,262.80 from ¥2,308,747,885.83, a growth of 0.9%[21] Future Plans - The company has completed the main equipment procurement for the expansion project in the second factory area, with installation underway[17] - The company plans to implement new, modified, and expanded projects in the second factory area, which have been approved by the shareholders[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[22] Stock Information - The total number of restricted shares at the beginning of the period was 57,109,218, with 2,986,962 shares released during the period[16] - The number of unrestricted shares held by the top ten unrestricted shareholders totals 55,511,352 shares[14] - The company has a stock incentive plan with a vesting period of 12, 24, and 36 months for certain shares[16] Taxation - The company reported a significant decrease in income tax expenses by 76.61%, amounting to ¥1,263,808.79 compared to ¥5,402,452.76 in the same period last year[10] - The company experienced a 164.80% increase in taxes and surcharges, amounting to ¥2,274,797.03, primarily due to an increase in value-added tax surcharges[10] Audit Status - The company has not yet audited the first quarter report for the current year[27]